Genocea Biosciences, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2006)
Status: Defunct (2022)

Organization Overview

First Clinical Trial
2012
NCT01667341
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Genocea Biosciences, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Communicable Diseases (Phase 2)

Herpes Genitalis (Phase 2)

Herpes Simplex (Phase 2)

Herpesviridae Infections (Phase 2)

Infections (Phase 2)

Lung Neoplasms (Phase 1)

Melanoma (Phase 2)

Pneumococcal Infections (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Pneumococcal (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 12